What is PE-22-28?
PE-22-28 is a synthetic peptide fragment derived from proenkephalin, an endogenous opioid precursor protein. It is widely referenced in neurochemical and peptide chemistry literature for its interaction with TREK-1, a two-pore domain potassium channel implicated in mood regulation and stress response. In laboratory settings, PE-22-28 is commonly studied for peptide structure, receptor interaction behavior, and analytical stability under controlled experimental conditions. Supplied in lyophilized form at 10 mg, it allows controlled reconstitution and precise experimental handling, with each batch independently third-party tested to verify identity and purity.
Mechanisms of Action
TREK-1 potassium channel inhibition by selectively blocking this two-pore domain channel, which plays a key role in regulating neuronal excitability and mood-related signaling pathways
Modulation of serotonergic activity downstream of TREK-1 inhibition, with research suggesting increased serotonin availability in relevant brain regions
Neuroprotective signaling via influence on ion channel activity, contributing to cellular stability under conditions of neurochemical stress
Structure-function interaction modeling with receptor binding sites, making it a useful tool compound for understanding peptide-channel dynamics in research settings
Benefits
Antidepressant-like effects observed in preclinical models, attributed to TREK-1 inhibition and resulting changes in serotonergic tone
Anxiolytic activity reported in research contexts, with PE-22-28 showing potential to reduce anxiety-related behaviors in animal model studies
Rapid onset of action noted in some research models compared to conventional antidepressant compounds, making it of interest for fast-acting neurological applications
High selectivity for TREK-1 over related potassium channel subtypes, supporting its use as a targeted research tool for dissecting channel-specific effects
Dosing
Strength | Injectable |
|---|---|
Low | 150mcg per day |
Medium | 500mcg per day |
High | 1000mcg per day or more |
Safety Profile
PE-22-28 is not approved for human or veterinary use and all safety data is derived from preclinical research settings. No significant adverse effects have been widely reported in animal model studies at research-relevant doses. As with all peptide compounds, proper laboratory handling, storage at -20°C, and sterile reconstitution practices are recommended to maintain stability and experimental integrity.
Stacking
Mood Lift Stack
PE-22-28
Selank
Semax
Citations
Djillani, A., et al. Proenkephalin-derived peptide PE-22-28 and TREK-1 channel inhibition. PubMed. https://pubmed.ncbi.nlm.nih.gov/16516337/
Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.
